<DOC>
	<DOCNO>NCT03018626</DOCNO>
	<brief_summary>This randomize , open-label , multi-center , phase 3 study evaluate efficacy R-ACVBP DA-EPOCH-R patient newly diagnose non-germinal b-cell-like diffuse large B-cell lymphoma</brief_summary>
	<brief_title>R-ACVBP DA-EPOCH-R Patients With Non-GCB DLBCL</brief_title>
	<detailed_description>Diffuse large B-cell lymphoma ( DLBCL ) common type non-Hodgkin 's lymphoma . According Hans ' algorithm , DLBCL identify 2 subtypes : germinal b-cell-like ( GCB ) non-germinal b-cell-like ( non-GCB ) . Approximately 50 60 % diffuse large-B cell lymphoma ( DLBCL ) non-GCB subtype DLBCL . Although introduction rituximab immunochemotherapy dramatically improve outcome patient DLBCL , The survival still poor non-GCB DLBCL patient treat R-CHOP . The LNH03-2B study show R-ACVBP regimen give long PFS ( 93 % vs. 74 % 3 year , p=0.0074 ) long OS ( 97 % vs. 83 % 3 year , p=0.0067 ) R-CHOP young patient non-GCB DLBCL . It also show R-ACVBP regimen give long PFS ( 87 % vs. 73 % 3 year , p=0.0074 ) long OS ( 92 % vs. 84 % 3 year , p=0.0067 ) R-CHOP young low-intermediate risk DLBCL patient . The LNH2003-3 study show high-risk ( 2/3 IPI factor ) DLBCL patient treat R-ACVBP follow auto-ASCT result 74 % PFS 76 % OS . Hematological toxic effect intensive regimen raise manageable . The CALGB study show DLBCL patient least 18 year age least stage II , DA-EPOCH-R regimen effective GCB non-GCB subtypes , 5-years TTP 67 % , EFS 58 % OS 68 % non-GCB subtype DLBCL . It encourage PETHEMA Group study show long-term follow-up untreated DLBCL patient poor prognosis , DA-EPOCH-R achieve 70.8 % EFS 76.4 % OS 10 year non-GCB subtype DLBCL . However efficacy R-ACVBP compare DA-EPOCH-R patient newly diagnose non-germinal b-cell-like diffuse large B-cell lymphoma remain unknown . All above-mentioned result lead u propose randomize trial compare R-ACVBP DA-EPOCH-R previously untreated patient non-GCB DLBCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>Patient histologically proven CD20+ diffuse large B cell lymphoma ( WHO Classification ) , aaIPI &gt; 1 , Age &gt; 18 &lt; 61 year , Negative HIV serologies 4 week Ability understand willingness sign write informed consent Any histological type lymphoma . Any history treat nontreated indolent lymphoma . Central nervous system meningeal involvement lymphoma . Contraindication drug contain chemotherapy regimen . Any serious active disease ( accord investigator 's decision ) . Poor renal function ( creatinin level &gt; 150Âµmol/l ) , poor hepatic function ( total bilirubin level &gt; 30mmol/l , transaminase &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.5 G/l platelet &lt; 100 G/l , unless relate bone marrow infiltration . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-germinal b-cell-like</keyword>
	<keyword>R-ACVBP</keyword>
	<keyword>DA-EPOCH-R</keyword>
</DOC>